Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Report 2026

The ornithine transcarbamylase deficiency (otc deficiency) market size has grown strongly in recent years. It will grow from $0.89 billion in 2025 to $0.95 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to limited treatment options and high disease burden, growing awareness of otc deficiency in neonates, early adoption of liver transplant and dietary management, increasing research in rare genetic disorders, rising prevalence of hyperammonemia-related complications.

The ornithine transcarbamylase deficiency (otc deficiency) market size is expected to see strong growth in the next few years. It will grow to $1.23 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to expanding pipeline of gene and mRNA-based therapies, increasing availability of enzyme replacement and protein engineering solutions, growing adoption of precision medicine approaches, rising investments in rare disease research, expansion of diagnostic testing and genetic screening programs. Major trends in the forecast period include rising adoption of gene therapy for otc deficiency, increasing focus on personalized and targeted treatment approaches, growing awareness about early diagnosis through genetic testing, rising demand for enzyme replacement and protein engineering therapies, increasing clinical emphasis on ammonia level monitoring and management.

The growing demand for gene therapies is expected to drive the growth of the ornithine transcarbamylase deficiency (OTC deficiency) market in the coming years. Gene therapy involves altering or manipulating a person's genetic material to treat or prevent disease. The rising prevalence of genetic disorders, which often have limited treatment options, has increased the demand for gene therapies, as they target the underlying cause rather than just managing symptoms. OTC deficiency demonstrates the potential of gene therapy by correcting the genetic mutation that disrupts the urea cycle, allowing targeted treatment to restore metabolic function and prevent toxic ammonia buildup. For example, in January 2024, the American Society of Gene & Cell Therapy, a US-based organization, reported that in Q4 2023, the number of gene therapies in Phase III trials increased by 10% from the previous quarter, marking the first rise since Q3 2022. Therefore, the growing demand for gene therapies is driving the growth of the OTC deficiency market.

Companies operating in the OTC deficiency market are focusing on developing innovative treatments, such as mRNA therapeutics, to enhance efficacy and address the underlying genetic cause of the condition. mRNA therapeutics use messenger RNA to instruct cells to produce specific proteins for therapeutic purposes, leveraging the body’s natural protein synthesis machinery. These therapies are being explored for genetic disorders, infectious diseases, and cancers. For instance, in June 2023, Arcturus Therapeutics Holdings Inc., a US-based biotechnology company, received Fast Track Designation from the FDA for ARCT-810, its mRNA therapeutic candidate for OTC deficiency. This designation is intended to accelerate the development and review process, offering benefits such as more frequent FDA interactions and priority review. ARCT-810 is designed to enable patients with OTC deficiency to produce functional OTC enzyme in their liver cells, addressing the root cause of the condition and potentially improving quality of life.

In November 2023, Zevra Therapeutics Inc., a US-based pharmaceutical company, acquired Acer Therapeutics Inc. for $91 million to strengthen its rare disease portfolio. Through this acquisition, Zevra aims to expand its assets in the rare disease sector and increase revenue potential. Acer Therapeutics Inc., a US-based company, develops therapies specifically for ornithine transcarbamylase deficiency.

Major companies operating in the ornithine transcarbamylase deficiency (otc deficiency) market are Thermo Fisher Scientific, Novartis AG, GlaxoSmithKline plc, Roche Holding AG, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc, Biogen Idec, Bausch Health Companies Inc, Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical Inc, Glenmark Pharmaceuticals Ltd., Nutricia, Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc, Arcturus Therapeutics, Regenxbio, OrphanPacific Inc, Ucyclyd Pharma Inc.

North America was the largest region in the ornithine transcarbamylase deficiency (OTC Deficiency) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ornithine transcarbamylase deficiency (otc deficiency) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ornithine transcarbamylase deficiency (otc deficiency) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the otc deficiency market by increasing costs for imported viral vectors, recombinant enzymes, and specialized laboratory equipment. These effects are most visible in gene therapy, enzyme replacement, and small molecule therapy segments across north america, europe, and asia-pacific. Tariffs have led to higher treatment costs and potential delays in therapy availability. However, they have also encouraged local production of critical components, enhanced regional supply chain resilience, and promoted domestic manufacturing of advanced therapies.

The ornithine transcarbamylase deficiency (otc deficiency) market research report is one of a series of new reports that provides ornithine transcarbamylase deficiency (otc deficiency) market statistics, including ornithine transcarbamylase deficiency (otc deficiency) industry global market size, regional shares, competitors with a ornithine transcarbamylase deficiency (otc deficiency) market share, detailed ornithine transcarbamylase deficiency (otc deficiency) market segments, market trends and opportunities, and any further data you may need to thrive in the ornithine transcarbamylase deficiency (otc deficiency) industry. This ornithine transcarbamylase deficiency (otc deficiency) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ornithine transcarbamylase (OTC) deficiency is a rare genetic disorder caused by mutations in the OTC gene, leading to a lack of the ornithine transcarbamylase enzyme, which is vital for the urea cycle that removes ammonia from the body. This deficiency results in hyperammonemia, causing symptoms such as vomiting, lethargy, seizures, and in severe cases, coma, especially in newborns.

The main products for treating OTC deficiency include DTX-301, SEL-313, SHP-641, and PRX-OTC. DTX-301 is an investigational AAV8-based gene therapy designed to deliver a functional OTC gene to liver cells. Treatment approaches include gene therapy, liver transplantation, dietary management, and other methods. Diagnosis typically involves genetic testing and measuring ammonia levels. End users of OTC deficiency treatments include hospitals, specialty clinics, research institutes, and other healthcare facilities.

The ornithine transcarbamylase deficiency market consists of revenues earned by entities by providing services such as genetic testing & diagnosis services, dietary management & nutrition services, clinical trials & research programs, medical consultation and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The ornithine transcarbamylase deficiency (OTC deficiency) market also includes sales of amino acid and protein supplements, gene therapies, nitrogen scavenging drugs, diagnostic and monitoring tests. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.